Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Isolated v-lesion represents a benign phenotype of vascular rejection of the kidney allograft - a retrospective study

M. Novotny, P. Hruba, P. Vichova, J. Maluskova, E. Honsova, O. Viklicky, M. Wohlfahrtova,

. 2018 ; 31 (10) : 1153-1163. [pub] 20180625

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19012638

Grant support
NV15-26519A MZ0 CEP Register

While the detrimental impact of the humoral acute vascular rejection (AVR) phenotype is recognized, the prognostic significance of isolated v-lesion (IV) remains unclear. In this retrospective single-centre study, AVR was found in 98 of 1015 patients (9.7%) who had undergone kidney transplantation in 2010-2014, with donor-specific antibodies (DSA) evaluated in all of them. The outcome of four AVR phenotypes was evaluated during median follow-up of 59 months; in 25 patients with IV, 18 with T-cell-mediated vascular rejection (TCMVR), 19 with antibody-mediated vascular rejection (AMVR) and 36 with suspected antibody-mediated rejection (sAMVR). AVR was diagnosed mainly by for-cause biopsy (81%) early after transplantation (median 19 POD) and appeared as mild-grade intimal arteritis. IV occurred in low-sensitized patients after the first transplantation (96%) in the absence of DSA. IV responded satisfactorily to treatment (88%), showed no persistence of rejection in surveillance biopsy, and had stable graft function, minimal proteinuria and excellent DCGS (96%). Contrary to that, Kaplan-Meier estimate of 3-year DCGS of AMVR was 66% (log-rank = 0.0004). Early IV represents a benign phenotype of AVR with a favourable outcome. This study prompts further research to evaluate the nature of IV before considering any change in the classification and management.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012638
003      
CZ-PrNML
005      
20201015145514.0
007      
ta
008      
190405s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/tri.13286 $2 doi
035    __
$a (PubMed)29855106
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Novotny, Marek $u Department of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
245    10
$a Isolated v-lesion represents a benign phenotype of vascular rejection of the kidney allograft - a retrospective study / $c M. Novotny, P. Hruba, P. Vichova, J. Maluskova, E. Honsova, O. Viklicky, M. Wohlfahrtova,
520    9_
$a While the detrimental impact of the humoral acute vascular rejection (AVR) phenotype is recognized, the prognostic significance of isolated v-lesion (IV) remains unclear. In this retrospective single-centre study, AVR was found in 98 of 1015 patients (9.7%) who had undergone kidney transplantation in 2010-2014, with donor-specific antibodies (DSA) evaluated in all of them. The outcome of four AVR phenotypes was evaluated during median follow-up of 59 months; in 25 patients with IV, 18 with T-cell-mediated vascular rejection (TCMVR), 19 with antibody-mediated vascular rejection (AMVR) and 36 with suspected antibody-mediated rejection (sAMVR). AVR was diagnosed mainly by for-cause biopsy (81%) early after transplantation (median 19 POD) and appeared as mild-grade intimal arteritis. IV occurred in low-sensitized patients after the first transplantation (96%) in the absence of DSA. IV responded satisfactorily to treatment (88%), showed no persistence of rejection in surveillance biopsy, and had stable graft function, minimal proteinuria and excellent DCGS (96%). Contrary to that, Kaplan-Meier estimate of 3-year DCGS of AMVR was 66% (log-rank = 0.0004). Early IV represents a benign phenotype of AVR with a favourable outcome. This study prompts further research to evaluate the nature of IV before considering any change in the classification and management.
650    _2
$a dospělí $7 D000328
650    _2
$a protilátky $x imunologie $7 D000906
650    _2
$a biopsie $7 D001706
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a rejekce štěpu $x imunologie $7 D006084
650    _2
$a přežívání štěpu $7 D006085
650    _2
$a HLA antigeny $x imunologie $7 D006680
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $7 D007166
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a ledviny $x imunologie $x patologie $7 D007668
650    _2
$a transplantace ledvin $x škodlivé účinky $7 D016030
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a fenotyp $7 D010641
650    _2
$a renální insuficience $x chirurgie $7 D051437
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a riziko $7 D012306
650    _2
$a T-lymfocyty $x imunologie $7 D013601
650    _2
$a časové faktory $7 D013997
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hruba, Petra $u Transplant Laboratory, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Vichova, Petra $u Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Maluskova, Jana $u Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Honsova, Eva $u Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Viklicky, Ondrej $u Department of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Transplant Laboratory, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Wohlfahrtova, Mariana $u Department of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
773    0_
$w MED00004553 $t Transplant international official journal of the European Society for Organ Transplantation $x 1432-2277 $g Roč. 31, č. 10 (2018), s. 1153-1163
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29855106 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20201015145511 $b ABA008
999    __
$a ok $b bmc $g 1391948 $s 1050943
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 31 $c 10 $d 1153-1163 $e 20180625 $i 1432-2277 $m Transplant international $n Transpl Int $x MED00004553
GRA    __
$a NV15-26519A $p MZ0
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Archiving options